Erythropoietin supports the survival of prostate cancer, but not growth and bone metastasis

Journal of Cellular Biochemistry

Volumn 114, Issue 11, 2013, Pages 2471-2478

  Shiozawa, Yusuke ^a   McGee, Samantha ^a   Pienta, Michael J ^a,b   McGregor, Natalie ^b   Jung, Younghun ^a   Yumoto, Kenji ^a   Wang, Jingcheng ^a   Berry, Janice E ^a   Pienta, Kenneth J ^b,c   Taichman, Russell S ^a  

^a UNIVERSITY OF MICHIGAN SCHOOL OF DENTISTRY   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; Erythropoietin; Growth; Metastasis; Prostate; Tumor

Indexed keywords

ERYTHROPOIETIN;

ANEMIA; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BONE METASTASIS; CANCER CELL CULTURE; CANCER GROWTH; CANCER SURVIVAL; CELL PROLIFERATION; CELL PROTECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; RISK ASSESSMENT;

CANCER; ERYTHROPOIETIN; GROWTH; METASTASIS; PROSTATE; TUMOR;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; BONE NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; ERYTHROPOIETIN; FLOW CYTOMETRY; HUMANS; MALE; MICE; MICE, SCID; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS;

EID: 84884222594     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.24592     Document Type: Article

References (41)

1. Acs G, Acs P, Beckwith SM, Pitts RL, Clements E, Wong K, Verma A,. 2001. Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res 61: 3561-3565.
2. Arcasoy MO,. 2008. The non-haematopoietic biological effects of erythropoietin. Br J Haematol 141: 14-31.
3. Arcasoy MO, Jiang X, Haroon ZA,. 2003. Expression of erythropoietin receptor splice variants in human cancer. Biochem Biophys Res Commun 307: 999-1007.
4. Arcasoy MO, Amin K, Vollmer RT, Jiang X, Demark-Wahnefried W, Haroon ZA,. 2005. Erythropoietin and erythropoietin receptor expression in human prostate cancer. Mod Pathol 18: 421-430.
5. Bahlmann FH, De Groot K, Spandau JM, Landry AL, Hertel B, Duckert T, Boehm SM, Menne J, Haller H, Fliser D,. 2004. Erythropoietin regulates endothelial progenitor cells. Blood 103: 921-926.
6. Brines M, Grasso G, Fiordaliso F, Sfacteria A, Ghezzi P, Fratelli M, Latini R, Xie QW, Smart J, Su-Rick CJ, et al. 2004. Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc Natl Acad Sci USA 101: 14907-14912.
7. Calvi LM, Adams GB, Weibrecht KW, Weber JM, Olson DP, Knight MC, Martin RP, Schipani E, Divieti P, Bringhurst FR, et al. 2003. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 425: 841-846.
8. Dempke W, Von Poblozki A, Grothey A, Schmoll HJ,. 2000. Human hematopoietic growth factors: Old lessons and new perspectives. Anticancer Res 20: 5155-5164.
9. Dicato M, Plawny L,. 2010. Erythropoietin in cancer patients: Pros and cons. Curr Opin Oncol 22: 307-311.
10. Dunlop EA, Percy MJ, Boland MP, Maxwell AP, Lappin TR,. 2006. Induction of signalling in non-erythroid cells by pharmacological levels of erythropoietin. Neurodegener Dis 3: 94-100.
11. Fandrey J, Dicato M,. 2009. Examining the involvement of erythropoiesis-stimulating agents in tumor proliferation (erythropoietin receptors, receptor binding, signal transduction), angiogenesis, and venous thromboembolic events. Oncologist 14 (Suppl 1): 34-42.
12. Feldman L, Wang Y, Rhim JS, Bhattacharya N, Loda M, Sytkowski AJ,. 2006. Erythropoietin stimulates growth and STAT5 phosphorylation in human prostate epithelial and prostate cancer cells. Prostate 66: 135-145.
13. Finucane ML, Slovic P, Mertz CK,. 2000. Public perception of the risk of blood transfusion. Transfusion 40: 1017-1022.
14. Folkman J,. 1995. Seminars in medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med 333: 1757-1763.
15. Gay LJ, Felding-Habermann B,. 2011. Contribution of platelets to tumour metastasis. Nat Rev Cancer 11: 123-134.
16. Hedley BD, Allan AL, Xenocostas A,. 2011. The role of erythropoietin and erythropoiesis-stimulating agents in tumor progression. Clin Cancer Res 17: 6373-6380.
17. Heeschen C, Aicher A, Lehmann R, Fichtlscherer S, Vasa M, Urbich C, Mildner-Rihm C, Martin H, Zeiher AM, Dimmeler S,. 2003. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood 102: 1340-1346.
18. Ingber D, Fujita T, Kishimoto S, Sudo K, Kanamaru T, Brem H, Folkman J,. 1990. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 348: 555-557.
19. Jelkmann W, Elliott S,. 2012. Erythropoietin and the vascular wall: The controversy continues. Nutr Metab Cardiovasc Dis In Press.
20. Jelkmann W, Laugsch M,. 2007. Problems in identifying functional erythropoietin receptors in cancer tissue. J Clin Oncol 25: 1627-1628, author reply 1628.
21. Jeong JY, Feldman L, Solar P, Szenajch J, Sytkowski AJ,. 2008. Characterization of erythropoietin receptor and erythropoietin expression and function in human ovarian cancer cells. Int J Cancer 122: 274-280.
22. Jubinsky PT, Krijanovski OI, Nathan DG, Tavernier J, Sieff CA,. 1997. The beta chain of the interleukin-3 receptor functionally associates with the erythropoietin receptor. Blood 90: 1867-1873.
23. Kataoka M, Moriya Y, Moriguchi Y, Iwai T, Fujimoto-Ouchi K, Shirane M, Kondoh K, Mori K,. 2010. Effect of erythropoietin on human tumor growth in xenograft models. Mol Med Rep 3: 95-101.
24. Leyland-Jones B,. 2003. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 4: 459-460.
25. Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, et al. 2001. Involvement of chemokine receptors in breast cancer metastasis. Nature 410: 50-56.
26. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH, Folkman J,. 1994. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79: 315-328.
27. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J,. 1997. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 88: 277-285.
28. Ribatti D,. 2010. Erythropoietin and tumor angiogenesis. Stem Cells Dev 19: 1-4.
29. Shiozawa Y, Taichman RS,. 2012. Getting blood from bone: An emerging understanding of the role that osteoblasts play in regulating hematopoietic stem cells within their niche. Exp Hematol 40: 685-694.
30. Shiozawa Y, Jung Y, Ziegler AM, Pedersen EA, Wang J, Wang Z, Song J, Wang J, Lee CH, Sud S, et al. 2010. Erythropoietin couples hematopoiesis with bone formation. PLoS ONE 5: e10853.
31. Shiozawa Y, Pedersen EA, Havens AM, Jung Y, Mishra A, Joseph J, Kim JK, Patel LR, Ying C, Ziegler AM, et al. 2011. Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. J Clin Invest 121: 1298-1312.
32. Sinclair AM, Coxon A, McCaffery I, Kaufman S, Paweletz K, Liu L, Busse L, Swift S, Elliott S, Begley CG,. 2010. Functional erythropoietin receptor is undetectable in endothelial, cardiac, neuronal, and renal cells. Blood 115: 4264-4272.
33. Spivak JL, Gascon P, Ludwig H,. 2009. Anemia management in oncology and hematology. Oncologist 14 (Suppl 1): 43-56.
34. Sun X, Cheng G, Hao M, Zheng J, Zhou X, Zhang J, Taichman RS, Pienta KJ, Wang J,. 2010. CXCL12/CXCR4/CXCR7 chemokine axis and cancer progression. Cancer Metastasis Rev 29: 709-722.
35. Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS, McCauley LK,. 2002. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res 62: 1832-1837.
36. Visnjic D, Kalajzic I, Gronowicz G, Aguila HL, Clark SH, Lichtler AC, Rowe DW,. 2001. Conditional ablation of the osteoblast lineage in Col2.3deltatk transgenic mice. J Bone Miner Res 16: 2222-2231.
37. Visnjic D, Kalajzic Z, Rowe DW, Katavic V, Lorenzo J, Aguila HL,. 2004. Hematopoiesis is severely altered in mice with an induced osteoblast deficiency. Blood 103: 3258-3264.
38. Westenfelder C, Baranowski RL,. 2000. Erythropoietin stimulates proliferation of human renal carcinoma cells. Kidney Int 58: 647-657.
39. Wright JR, Ung YC, Julian JA, Pritchard KI, Whelan TJ, Smith C, Szechtman B, Roa W, Mulroy L, Rudinskas L, et al. 2007. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol 25: 1027-1032.
40. Wu TT, Sikes RA, Cui Q, Thalmann GN, Kao C, Murphy CF, Yang H, Zhau HE, Balian G, Chung LW,. 1998. Establishing human prostate cancer cell xenografts in bone: Induction of osteoblastic reaction by prostate-specific antigen-producing tumors in athymic and SCID/bg mice using LNCaP and lineage-derived metastatic sublines. Int J Cancer 77: 887-894.
41. Yasuda Y, Fujita Y, Matsuo T, Koinuma S, Hara S, Tazaki A, Onozaki M, Hashimoto M, Musha T, Ogawa K, et al. 2003. Erythropoietin regulates tumour growth of human malignancies. Carcinogenesis 24: 1021-1029.